bone marker

bone marker

Any biochemical marker that indicates bone breakdown, which can be used to predict individual fracture risk when bone mineral density measurement does not provide a clear answer.

Bone markers
Bone formation markers
• Serum total alkaline phosphatase;
• Serum bone—specific alkaline phosphatase;
• Serum osteocalcin;
• Serum type-1 procollagen.

Bone resorption markers
• Urine hydroxyproline;
• Urine total pyridinoline (PYD);
• Urine free deoxypyridinoline (DPD);
• Urine collagen type-1 cross-linked N-telopeptide (NTX);
• Urine or serum collagen type-1 cross-linked C-telopeptide (CTX);
• Bone sialoprotein (BSP);
• Tartrate-resistant acid phosphatase 5b.

bone marker

Lab medicine Any protein degradation product that indicates bone breakdown. See N-telopeptides.
References in periodicals archive ?
The serum was aliquoted into microtubes, and frozen at -84[degrees]C until the bone marker assays were performed.
It increases the growth of cells called osteoblasts, which help build your bones, and increases expression of collagen and bone marker proteins.
We show that this prevention in areal bone mineral density and micro-CT parameters results from the stimulation of bone formation, demonstrable in vivo by histomorphometry, bone marker measurements, and quantitative PCR.
On Tuesday, Algeta announced positive preliminary bone marker results in a phase IIa study evaluating the drug in breast cancer patients with bone metastases.
Sedentary SCI subjects in this study had higher bone marker formation (BAP) rates than the active SCI subjects, a result which contrasts with studies in able-bodied athletes, in whom exercise has had a positive influence on bone density formation (9,10).
The preferred measurement the biological markers of pyridinolines are in twenty-four (24) hours urine collections Dpd is the bone marker of choice for bone resorption.
For a bone marker to be useful in assessing the rate of bone turnover and monitoring therapy, the following attributes are required:
Menopause was the chief factor influencing the variations in bone marker measurements in women, with the mean level of S-OC and S-BAP increasing by 21% and 41%, respectively.
These data give an insight into the bone marker response to very short training protocols, the data suggest at early time points in a training protocol bone formation and bone resorption are both suppressed.
Yesterday, Algeta announced positive preliminary bone marker results in a phase IIa study evaluating its drug candidate Alpharadin in breast cancer patients with bone metastases.